Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intra-Cellular Therapies stock on March 24th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 4/1/2025.
• Sold $1,001 - $15,000 in shares of W. R. Berkley NYSE: WRB on 4/1/2025.
• Sold $15,001 - $50,000 in shares of GoDaddy NYSE: GDDY on 4/1/2025.
• Purchased $1,001 - $15,000 in shares of Ford Motor NYSE: F on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 3/31/2025.
• Purchased $1,001 - $15,000 in shares of Boeing NYSE: BA on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Hologic NASDAQ: HOLX on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/31/2025.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI remained flat at $131.87 during trading hours on Friday. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The company's 50 day moving average is $130.29 and its two-hundred day moving average is $104.37.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their price objective for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and decreased their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Piper Sandler reiterated a "neutral" rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Sunday. They issued a "hold" rating for the company. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $106.23.

Institutional Trading of Intra-Cellular Therapies

Institutional investors and hedge funds have recently made changes to their positions in the stock. SeaCrest Wealth Management LLC acquired a new stake in Intra-Cellular Therapies in the 1st quarter worth approximately $251,000. Merit Financial Group LLC raised its position in shares of Intra-Cellular Therapies by 13.5% in the first quarter. Merit Financial Group LLC now owns 2,798 shares of the biopharmaceutical company's stock valued at $369,000 after purchasing an additional 333 shares during the period. GAMMA Investing LLC lifted its stake in shares of Intra-Cellular Therapies by 12,952.8% in the first quarter. GAMMA Investing LLC now owns 98,940 shares of the biopharmaceutical company's stock worth $130,520,000 after buying an additional 98,182 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Intra-Cellular Therapies by 124.3% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 133 shares during the period. Finally, Wellington Management Group LLP grew its stake in Intra-Cellular Therapies by 1.6% in the 4th quarter. Wellington Management Group LLP now owns 1,033,743 shares of the biopharmaceutical company's stock valued at $86,338,000 after buying an additional 16,096 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.